Law360, New York (May 06, 2010, 2:46 PM ET) -- Doubly determined to prevent incursions by generics makers, Eli Lilly & Co. has filed a second infringement action against Watson Pharmaceuticals Inc. over its effort to develop a knockoff version of popular postmenopausal osteoporosis treatment Evista.
The complaint, filed Wednesday in the U.S. District Court for the District of Nevada, shadows an identical lawsuit launched Monday in federal court in Indiana alleging that Watson infringed three patents while seeking regulatory approval of a generic version of Evista (raloxifene).
Watson’s abbreviated new drug application before the U.S....
Lilly Redoubles Fight Against Watson Evista Generic
To view the full article, take a free trial now.
